CytoMed Therapeutics Limited Ordinary Shares

CytoMed Therapeutics announced Friday that it received a Nasdaq notice of non-compliance after its closing bid price stayed below $1 for 30 consecutive business days. The company has until April 5, 2027, to restore compliance by keeping its closing bid price at or above $1 for at least 10 consecutive business days. CytoMed may qualify for another 180-day extension if it meets Nasdaq's other listing requirements, including the minimum market value of publicly held shares. A written notice outlining its intention to cure the deficiency must be submitted to Nasdaq during the second period, with a reverse stock split among the possible measures. Shares fell 5.81%.

CytoMed Therapeutics Limited said it received a notice from Nasdaq on October 6, 2026, stating that the closing bid price of its ordinary shares had been below the minimum US$1.00 per share requirement under Nasdaq Listing Rule 5550(a)(2) for the last 30 consecutive business days. The Singapore-based clinical stage biopharmaceutical company, which trades on Nasdaq under the symbol GDTC, said the notification letter has no current effect on the listing or trading of its ordinary shares. Under Nasdaq Listing Rule 5810(c)(3)(A), CytoMed has a 180 calendar day compliance period, running until April 5, 2027, to regain compliance. The company would regain compliance if its closing bid price is US$1.00 per share or higher for at least ten consecutive business days at any point during that period, and if it fails to do so by April 5, 2027, it may be eligible for an additional 180-day compliance period provided it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, apart from the minimum bid price requirement. CytoMed said the letter does not affect its business operations and that it intends to take all reasonable measures to regain compliance within the prescribed grace period.